Background: The effect of booster vaccinations with the coronavirus virus disease (COVID-19) vaccine on people living with HIV (PLWH) remains unknown. In this study, we aimed to investigate the immunogenicity and effectiveness of booster doses of the COVID-19 vaccine in PLWH.
Methods: Literature research was done through the PubMed, Embase, Cochrane Review, and Web of Science databases up to 4 July 2023. Pooled estimates were calculated and compared using the DerSimonian and Laird method for a random effects model. Randomized control trials and observational studies were both considered for inclusion.
Results: We included 35 eligible studies covering 30,154 PLWH. The pooled immune response rate (IRR) of PLWH after the COVID-19 booster vaccination was 97.25% (95% confidence interval [CI], 93.81-99.49), and similar to healthy control (HC) (risk ratio [RR] = 0.98, 95% CI, 0.96-1.00). The pooled IRR for PLWH with CD4 T-cell counts ≤ 200 was 86.27 (95% CI, 65.35-99.07). For Omicron variants, the pooled IRR for PLWH after booster dose was 74.07% (95% CI, 58.83-89.30), and the risk of IRR was reduced by 10% in PLWH compared with HC (RR = 0.90, 95% CI, 0.80-1.00). The T-cell immune response of PLWH was found to be comparable to HC ( ≥ 0.05). Subgroup analyses revealed that mRNA vaccines produced a relatively high IRR in PLWH compared to other vaccines. In addition, the results showed that booster vaccination appeared to further reduce the risk of COVID-19-related infections, hospitalizations, and deaths compared with the primary vaccination.
Conclusion: It was shown that booster vaccination with the COVID-19 vaccine provided a high IRR in PLWH and still produced a desirable moderate IRR in PLWH with a CD4 T-cell count of ≤ 200. Importantly, the humoral and T-cell responses to booster vaccination in PLWH were comparable to HC, and similar results were observed with the SARS-CoV-2 Omicron variant. Our review strongly emphasizes the effect of mRNA vaccine booster vaccination in PLWH on eliciting desirable protective IRR. Furthermore, booster vaccination appears to further reduce the risk of COVID-19 infection, hospitalization, and death in PLWH compared to primary vaccination. However, more evidence is needed to confirm its effectiveness.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591097 | PMC |
| http://dx.doi.org/10.3389/fmed.2023.1275843 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long COVID-19 in pregnancy: increased risk but modest incidence following mild Omicron infection in a boosted obstetric cohort during endemicity.
Am J Obstet Gynecol
March 2025
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; National Centre for Infectious Diseases, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore; Department of Infectious Diseases, Singapore General Hospital, Singapore. Electronic address:
Background: Significant heterogeneity has been reported in estimates of long-term sequelae following SARS-CoV-2 infection in pregnant women, and most studies were conducted pre-Omicron and pre-dated vaccination rollout. Less severe COVID-19 attributed to milder Omicron may potentially attenuate risk of post-COVID-19 sequelae.
Objective: We sought to examine long-term risk of new-incident multi-systemic sequelae following SARS-CoV-2 Delta/Omicron infection in a population-based cohort of pregnant women, contrasted against a)test-negatives; b)infected non-pregnant women of childbearing age.
Modulation of germinal center and antibody dynamics via ipsilateral versus contralateral immunization against SARS-CoV-2.
J Immunol
March 2025
Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Human clinical trials have reported immunological outcomes can differ between ipsilateral (same side) and contralateral (alternate sides) prime-boost vaccination. However, our mechanistic understanding of how keeping or shifting the anatomical sites of immunization impacts the resultant germinal centers (GCs) and antibody responses is limited. Here, we use an adjuvanted SARS-CoV-2 spike vaccine to dissect GC dynamics in draining lymph nodes and serological outcomes following ipsilateral or contralateral prime-boost vaccination in C57BL/6 mice.
View Article and Find Full Text PDFHPV vaccination willingness among 3,081 secondary school parents in China's capital.
Hum Vaccin Immunother
December 2025
Department of Planned Immunization, Chaoyang District Centre for Disease Control and Prevention, Beijing, China.
Assessing knowledge of HPV and HPV vaccine and vaccine willingness among Beijing secondary school parents, and identifying decision-influencing factors. Selected via multi-stage stratified sampling, 3,081 Chaoyang secondary school students' parents participated in a June-August 2024 study. They completed a questionnaire assessing HPV knowledge, vaccine awareness, and vaccination willingness.
View Article and Find Full Text PDFSWOT strategy for future global health security: insights from Indonesia, Cambodia, Vietnam, Dominican Republic, Ghana, and the Republic of Korea using the World Health Organization International Health Regulations monitoring tool.
Osong Public Health Res Perspect
March 2025
Division of International Affairs, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
Article Synopsis
- The study analyzed the health security capacities of six countries (Indonesia, Cambodia, Vietnam, Dominican Republic, Ghana, and South Korea) in implementing WHO International Health Regulations.
- Data was collected from various sources, including health security indices, and a SWOT analysis was conducted to identify strengths, weaknesses, opportunities, and threats affecting health security in these nations.
- Key findings highlighted strong early warning systems and immunization opportunities but also revealed weaknesses in legal frameworks and human resources, as well as threats like biosafety issues and communication challenges during public health emergencies.
Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
Vaccine
March 2025
Medical Evidence, Vaccines & Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Background: Booster doses of COVID-19 vaccines are required to maintain protection against SARS-CoV-2. However, real-world evidence from South America, needed to inform optimal vaccination strategies, is lacking. Herein, we present the final analysis of REFORCO-Brazil, a large-scale assessment of relative vaccine effectiveness (rVE) of second boosters (vs first boosters) against hospitalization with COVID-19.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!